keyword
MENU ▼
Read by QxMD icon Read
search

TTP

keyword
https://www.readbyqxmd.com/read/28339889/therapeutic-efficacy-of-anfibatide-in-a-murine-model-of-thrombotic-thrombocytopenic-purpura-ttp
#1
Liang Zheng, Yingying Mao, Mandy Li, Xiangrong Dai, Benjamin Li, X Long Zhen
No abstract text is available yet for this article.
March 1, 2017: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28339195/the-electronic-configuration-and-ligand-nature-of-five-coordinate-iron-porphyrin-carbene-complexes-an-experimental-study
#2
Yulong Liu, Wei Xu, Jing Zhang, William Fuller, Charles E Schulz, Jianfeng Li
The five coordinate iron porphyrin carbene complexes [Fe(TPP)(CCl<u>2</u>)] (TPP = tetraphenylporphyrin), [Fe(TTP)(CCl<u>2</u>)] (TTP = tetratolylporphyrin) and [Fe(TFPP)(CPh<u>2</u>)] (TFPP = tetra(pentafluorophenyl)porphin), utilizing two types of carbene ligands (CCl<u>2</u> and CPh<u>2</u>), have been investigated by single crystal X-ray, XANES (X-ray Absorption Near Edge Spectroscopy), Mössbauer, NMR and UV-vis spectros-copies. The XANES unambiguously suggested the iron(II) oxida-tion state of the complexes...
March 24, 2017: Journal of the American Chemical Society
https://www.readbyqxmd.com/read/28333956/discriminating-between-hur-and-ttp-binding-sites-using-the-k-spectrum-kernel-method
#3
Shweta Bhandare, Debra S Goldberg, Robin Dowell
BACKGROUND: The RNA binding proteins (RBPs) human antigen R (HuR) and Tristetraprolin (TTP) are known to exhibit competitive binding but have opposing effects on the bound messenger RNA (mRNA). How cells discriminate between the two proteins is an interesting problem. Machine learning approaches, such as support vector machines (SVMs), may be useful in the identification of discriminative features. However, this method has yet to be applied to studies of RNA binding protein motifs. RESULTS: Applying the k-spectrum kernel to a support vector machine (SVM), we first verified the published binding sites of both HuR and TTP...
2017: PloS One
https://www.readbyqxmd.com/read/28325251/interferon-induced-thrombotic-microangiopathy-tma-analysis-and-concise-review
#4
REVIEW
Ajay Kundra, Jen Chin Wang
Interferon (IFN) has been associated with development of thrombotic microangiopathy including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). We reviewed literature from the earliest reported association in 1993, to July 2016 and found 68 cases. Analysis of this data shows: (1) Mean age at diagnosis was 47 years (95% CI, 44-50). (2) Majority of cases were seen where IFN was used for the treatment of chronic myelogenous leukemia (CML), multiple sclerosis (MS), chronic hepatitis C virus infection (HCV) and one case each for hairy cell leukemia (HCL) and Sezary syndrome...
April 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28324920/an-open-label-randomized-parallel-phase-ii-trial-to-evaluate-the-efficacy-and-safety-of-a-cremophor-free-polymeric-micelle-formulation-of-paclitaxel-as-first-line-treatment-for-ovarian-cancer-a-korean-gynecologic-oncology-group-study-kgog-3021
#5
Shin-Wha Lee, Yong-Man Kim, Chi Heum Cho, Young Tae Kim, Seok Mo Kim, Soo Young Hur, Jae-Hoon Kim, Byoung-Gie Kim, Seung-Cheol Kim, Hee-Sug Ryu, Soon Beom Kang
Purpose: Genexol-PM is a biodegradable cremophor EL-free polymeric micelle formulation of paclitaxel. Here we compared efficacy and safety of Genexol-PM plus carboplatin vs. Genexol plus carboplatin for ovarian cancer treatment. Materials and Methods: In this multicenter, randomized, phase II study, patients with FIGO IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 AUC carboplatin every three weeks (6 cycles)...
March 21, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28319203/relationship-between-low-tube-voltage-70-kv-and-the-iodine-delivery-rate-idr-in-ct-angiography-an-experimental-in-vivo-study
#6
Michael M Lell, Ulrike Fleischmann, Hubertus Pietsch, Johannes G Korporaal, Ulrike Haberland, Andreas H Mahnken, Thomas G Flohr, Michael Uder, Gregor Jost
OBJECTIVE: Very short acquisition times and the use of low-kV protocols in CTA demand modifications in the contrast media (CM) injection regimen. The aim of this study was to optimize the use of CM delivery parameters in thoraco-abdominal CTA in a porcine model. MATERIALS AND METHODS: Six pigs (55-68 kg) were examined with a dynamic CTA protocol (454 mm scan length, 2.5 s temporal resolution, 70 s total acquisition time). Four CM injection protocols were applied in a randomized order...
2017: PloS One
https://www.readbyqxmd.com/read/28303751/vasoactive-peptides-associate-with-treatment-outcome-ofbevacizumab-containing-therapy-in-metastatic-colorectal-cancer
#7
Helga Hagman, Pär-Ola Bendahl, Olle Melander, Jan Sundberg, Anders Johnsson, Mattias Belting
BACKGROUND: Hypertension is a common early adverse event of anti-angiogenic treatment of cancer and may associate with treatment response. However, blood pressure measurement as a surrogate response biomarker has methodological limitations, and predictive biomarkers of angiogenesis inhibitors are lacking. In disease associated with hypertension, vasoactive peptides have been linked to cardiovascular pressure load. Here, we have explored potential associations between circulating levels of vasoactive peptides and tumor response during bevacizumab-containing treatment of colorectal cancer...
March 17, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28302726/the-rna-binding-protein-tristetraprolin-ttp-is-a-critical-negative-regulator-of-the-nlrp3-inflammasome
#8
Moritz Haneklaus, John D O'Neil, Andrew R Clark, Seth L Masters, Luke A J O'Neill
The NLRP3 inflammasome is a central regulator of inflammation in many common diseases, including atherosclerosis and Type 2 diabetes, driving the production of pro-inflammatory mediators such as IL-1β and IL-18. Due to its function as an inflammatory gatekeeper, expression and activation of NLRP3 need to be tightly regulated. In this study, we highlight novel post-transcriptional mechanisms that can modulate NLRP3 expression. We have identified the RNA-binding protein Tristetraprolin (TTP) as a negative regulator of NLRP3 in human macrophages...
March 16, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28302348/cone-beam-ct-guided-chemoembolization-of-probable-hepatocellular-carcinomas-smaller-than-1-cm-in-patients-at-high-risk-of-hepatocellular-carcinoma
#9
Jin Woo Choi, Hyo-Cheol Kim, Jeong-Hoon Lee, Su Jong Yu, Eun Ju Cho, Min-Uk Kim, Saebeom Hur, Myungsu Lee, Hwan Jun Jae, Jin Wook Chung
PURPOSE: To evaluate the effectiveness and safety of cone-beam computed tomography (CT)-guided chemoembolization for probable hepatocellular carcinomas (HCCs) smaller than 1 cm in patients at high risk for HCC. MATERIALS AND METHODS: From December 2009 to May 2014, 57 patients (43 male and 14 female; mean age, 61.1 y) at high risk for HCC underwent cone-beam CT-guided conventional chemoembolization for 79 treatment-naive probable HCCs < 1 cm. Probable HCCs were diagnosed when hepatic nodules showed arterial enhancement and washout on dynamic CT or magnetic resonance images...
March 14, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28299600/sorafenib-a-review-in-hepatocellular-carcinoma
#10
REVIEW
Gillian M Keating
Sorafenib (Nexavar(®)) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with advanced HCC, which showed significantly longer median overall survival (OS) and time to radiological progression (TTP) with sorafenib 400 mg twice daily than with placebo, with no significant between-group difference in the median time to symptomatic progression (TTSP)...
March 15, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28288572/a-multi-center-phase-ii-study-and-biomarker-analysis-of-combined-cetuximab-and-modified-folfiri-as-second-line-treatment-in-patients-with-metastatic-gastric-cancer
#11
Xin Liu, Weijian Guo, Wen Zhang, Jiliang Yin, Jun Zhang, Xiaodong Zhu, Tianshu Liu, Zhiyu Chen, Biyun Wang, Jianhua Chang, Fangfang Lv, Xiaonan Hong, Huijie Wang, Jialei Wang, Xinmin Zhao, Xianghua Wu, Jin Li
BACKGROUND: To evaluate the efficacy of cetuximab combined with modified FOLFIRI (mFOLFIRI) as a second-line treatment in metastatic gastric cancer patients and to identify potential biomarkers of clinical outcomes. METHODS: All 61 patients received an initial intravenous (IV) dose of cetuximab (400 mg/m(2)) and weekly doses (250 mg/m(2)) thereafter, starting on day 1. On day 2 of each 14-day period, patients received IV irinotecan (180 mg/m(2)), leucovorin (200 mg/m(2)), and an IV bolus dose of 5-FU (400 mg/m(2)) followed by a continuous infusion of 5-FU (2400 mg/m(2)) for 46 h...
March 14, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28284031/immunoparesis-in-igm-gammopathies-as-a-useful-biomarker-to-predict-disease-progression
#12
Marcio Andrade-Campos, Ilda Murillo-Flórez, Ramón García-Sanz, Pilar Giraldo
BACKGROUND: The management of IgM monoclonal gammopathies undetermined significance (IgM-MGUS) and Waldenstrom's macroglobulinemia (WM) may be challenging. Modern immunoassays that quantify specific monoclonal heavy and light chain immunoglobulins are promising for their use in these applications. METHODS: Ninety consecutive patients (39 IgM-MGUS, 32 indolent WM [iWM], and 19 WM) seen between January 2007 and March 2014 were analyzed. Heavy/light chain (HLC) and serum free light chains assays (FLC) were determined at diagnosis to study their utility as biomarkers in IgM monoclonal gammopathies...
March 11, 2017: Clinical Chemistry and Laboratory Medicine: CCLM
https://www.readbyqxmd.com/read/28279857/performance-of-two-blood-culture-systems-to-detect-anaerobic-bacteria-is-there-any-difference
#13
Manica Mueller-Premru, Samo Jeverica, Lea Papst, Elisabeth Nagy
We studied the performance characteristics of two blood culture (BC) bottles/systems, (i) BacT/ALERT-FN Plus/3D (bioMérieux, Marcy l'Étoile, France) and (ii) BACTEC-Lytic/9000 (Becton Dickinson, Sparks, USA) for detection of growth and time-to-positivity (TTP) against a balanced and diverse collection of anaerobic bacterial strains (n = 48) that included reference strains (n = 19) and clinical isolates (n = 29) of 32 species (15 Gram-negative and 17 Gram-positive) was tested. Standard suspension of bacteria was inoculated to each bottle in duplicates and incubated in the corresponding system...
March 6, 2017: Anaerobe
https://www.readbyqxmd.com/read/28278446/fluorocholine-pet-ct-predicts-skeletal-progression-skeletal-event-and-cancer-specific-survival-in-patients-with-biochemical-relapse-for-prostate-cancer
#14
Fabio Zattoni, Emanuela Agostini, Francesco Cattaneo, Marco Maruzzo, Umberto Basso, Filiberto Zattoni, Laura Evangelista
PURPOSE: The aim of our study is to evaluate the prognostic impact of (18)F-Choline (FCh) positron emission tomography (PET)/computed tomography (CT), CT alone and methylene diphophonate bone scan (MDP-BS) in prostate cancer (PCa) patients with biochemical relapse. METHODS: We retrospectively selected 58 patients who underwent, between June 2010 and February 2013, both FCh-PET/CT and MDP-BS within a maximum time interval of 5months. All patients had a biochemical PCa recurrence after radical prostatectomy and/or radiation therapy...
February 24, 2017: Clinical Imaging
https://www.readbyqxmd.com/read/28277033/efficacy-of-hydralazine-and-valproate-in-cutaneous-t-cell-lymphoma-a-phase-ii-study
#15
Jose Ramiro Espinoza-Zamora, Juan Labardini-Méndez, Alejandro Sosa-Espinoza, Celia López-González, Magnolia Vieyra-García, Myrna Candelaria, Valentin Lozano-Zavaleta, Diana Vanesa Toledano-Cuevas, Nidia Zapata-Canto, Eduardo Cervera, Alfonso Dueñas-González
OBJECTIVES: To evaluate the activity and safety hydralazine and valproate (Transkrip® in cutaneous T-cell lymphoma (CTCL). METHODS: Previously untreated and progressive/refractory CTCL patients received hydralazine at 83 mg or 182 mg/day for slow and rapid acetylators respectively plus magnesium valproate at a total dose of 30 mg/Kg t.i.d daily in continuous 28-day cycles in this phase II study. The primary objective was overall response rate (ORR) measured by the modified severity weighted assessment tool (m-SWAT), secondary end-points were time to response (TTR), time to progression (TTP), duration of response (DOR), progression-free survival (PFS), overall survival (OS) and safety...
February 15, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28272232/continuous-dose-intense-temozolomide-and-cisplatin-in-recurrent-glioblastoma-patients
#16
Yu Wang, Xiangyi Kong, Yi Guo, Renzhi Wang, Wenbin Ma
In glioblastoma multiforme (GBM), both temozolomide (TMZ) and cisplatin are very active at various toxic levels. Previous studies demonstrated that cisplatin with the standard regimen of TMZ is active in patients suffering from recurrent GBM, generating a moderate level of toxicity. Also, continuous dose-intense TMZ is a helpful therapy for patients with recurrent GBM. We have conducted a research to evaluate the security and effectiveness of cisplatin with constant dose-intense TMZ for reduplicative GBM. The time to progression (TTP) and progression-free survival (PFS) at 6 months (PFS-6) was the major end point...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28270291/feasibility-study-of-low-dose-prostate-ct-perfusion-on-third-generation-dual-source-ct
#17
Gumuyang Zhang, Hao Sun, Huadan Xue, Yun Wang, Jixiang Liang, Kai Xu, Ming Wang, Man Wang, Zhengyu Jin
Objective To investigate the feasibility of using low-dose prostate CT perfusion (pCTP)on a third-generation dual-source CT. Methods Nine patients with elevated prostate-specific antigen underwent pCTP before having prostate biopsy. We measured the blood flow (BF),blood volume (BV),mean transit time (MTT),permeability surface (PS),and time to peak(TTP)of both lesions and normal prostate tissue. The effective dose (ED)was calculated. Results Of the 9 cases,6 were prostate cancers and 3 were prostate hyperplasia with chronic inflammation...
February 20, 2017: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
https://www.readbyqxmd.com/read/28265287/pernicious-anemia-associated-cobalamin-deficiency-and-thrombotic-microangiopathy-case-report-and-review-of-the-literature
#18
Farhanah Yousaf, Bruce Spinowitz, Chaim Charytan, Marilyn Galler
A 43-year-old Hispanic male without significant previous medical history was brought to emergency department for syncope following a blood draw to investigate a 40 lbs weight loss during the past 6 months associated with decreased appetite and progressive fatigue. The patient also reported a 1-month history of jaundice. On examination, he was hemodynamically stable and afebrile with pallor and diffuse jaundice but without skin rash or palpable purpura. Normal sensations and power in all extremities were evident on neurological exam...
2017: Case Reports in Medicine
https://www.readbyqxmd.com/read/28265004/gain-of-function-mutation-of-tristetraprolin-impairs-negative-feedback-control-of-macrophages-in-vitro-yet-has-overwhelmingly-anti-inflammatory-consequences-in-vivo
#19
John D O'Neil, Ewan A Ross, Michael L Ridley, Qize Ding, Tina Tang, Dalya R Rosner, Thomas Crowley, Deepak Malhi, Jonathan L Dean, Tim Smallie, Christopher D Buckley, Andrew R Clark
The mRNA destabilizing factor tristetraprolin (TTP) binds in a sequence-specific manner to the 3' untranslated regions of many pro-inflammatory mRNAs and recruits complexes of nucleases to promote rapid mRNA turnover. Mice lacking TTP develop a severe, spontaneous inflammatory syndrome characterized by over-expression of tumor necrosis factor and other inflammatory mediators. However, TTP also employs the same mechanism to inhibit the expression of the potent anti-inflammatory cytokine interleukin 10. Perturbation of TTP function may therefore have mixed effects on inflammatory responses, either increasing or decreasing the expression of pro-inflammatory factors via direct or indirect mechanisms...
March 6, 2017: Molecular and Cellular Biology
https://www.readbyqxmd.com/read/28260922/metronomic-treatment-of-advanced-non-small-cell-lung-cancer-with-daily-oral-vinorelbine-a-phase-i-trial
#20
Sylvia Guetz, Amanda Tufman, Joachim von Pawel, Achim Rittmeyer, Astrid Borgmeier, Pierre Ferré, Birgit Edlich, Rudolf Maria Huber
MICRO-ABSTRACT: In a Phase I dose-finding study of metronomic daily oral vinorelbine in advanced non-small-cell lung cancer, a recommended dose was established for this therapeutic approach. In addition, this trial revealed promising efficacy data and an acceptable tolerability profile. The observed vinorelbine blood concentrations suggest continuous anti-angiogenic coverage. INTRODUCTION: We present a Phase I dose-finding study investigating metronomic daily oral vinorelbine (Navelbine(®) Oral, NVBo) in advanced non-small-cell lung cancer (NSCLC)...
2017: OncoTargets and Therapy
keyword
keyword
7199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"